Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Nov 19, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding giredestrant (Announcement of Phase III lidERA Study Results)
TOKYO, November 19, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on November 18, regarding the results of the interim analysis of the global Phase III clinical trial (lidERA) evaluating giredestrant in estrogen receptor (ER)-positive early-stage breast cancer. The study met its primary endpoint.
The detailed data will be presented at an upcoming medical meeting.
Please refer to the link below for details of the press release:
Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp